Cryoport Systems Nominated for Three APCGTEA Awards 

We’re proud to share that Cryoport Systems has been officially nominated for three prestigious categories in the 2025 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA). These nominations highlight the strength of our innovation, commitment to quality, and enduring partnership with the advanced therapies community across the region.  

Our nominations include:  

  • Best Cell & Gene Therapy Supplier – Cell Processing Systems 
  • Best Cell & Gene Therapy Supplier – Supply Chain Excellence 
  • Best Clinical Trial Logistics Provider – Cell & Gene Therapy 

This recognition reflects the dedication of our global teams, the trust of our clients, and our ongoing mission to Enable the Outcome™ for every therapy, every time.  

The winners of the APCGTEA are selected entirely via community voting, by professionals in the biopharma industry. That means your voice matters! Help us bring this home by casting your vote here:  

 Cast Your Vote
Voting closes on 27 June 2025.  

 We’re honored to be recognized among the finalists and energized to keep raising the standard in cell and gene therapy supply chain services. Thank you for your support, and for helping us continue to deliver certainty in the most critical moments of the CGT journey.  

Category: Articles

What to read next

Addressing the EMEA Cold Chain Challenge for Cell and Gene Therapies: Cryoport Systems Featured in Labiotech.eu
Articles
05/19/2025

Addressing the EMEA Cold Chain Challenge for Cell and Gene Therapies: Cryoport Systems Featured in Labiotech.eu

In a recent Labiotech.eu article, Florent Belon, Managing Director for Cryoport Systems in France, discusses how regulatory diversity, infrastructure gaps, and extreme climate variation across EMEA intensify the need for customized, compliant cold chain solutions. 

Read More

Read More
New Article with Contract Pharma: Minimizing Capital Expenditures through Supply Chain Integration
Articles
05/01/2025

New Article with Contract Pharma: Minimizing Capital Expenditures through Supply Chain Integration

Cryoport Systems has been featured in a new Contract Pharma article, “Minimizing Capital Expenditures through Supply Chain Integration.” This article explores how an integrated supply chain partner like Cryoport Systems helps organizations reduce risk, preserve capital, and gain the flexibility to scale without the burden of building it all themselves.

Read More

Read More
Cryoport Systems Featured in Contract Pharma: The Power of an Integrated Supply Chain
Articles
04/22/2025

Cryoport Systems Featured in Contract Pharma: The Power of an Integrated Supply Chain

Contract Pharma recently featured Cryoport Systems in a new Q&A article spotlighting our integrated, end-to-end supply chain platform for cell and gene therapies. The piece highlights insights from Matthew Frazzetta, Vice President of Global Accounts, BioServices at Cryoport Systems, and explores how we are supporting the growing needs of life sciences companies around the world. 

Read More

Read More